NCT00695643
Terminated
Phase 3
Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Overview
- Phase
- Phase 3
- Intervention
- Mesalazine
- Conditions
- Diverticulitis
- Sponsor
- Dr. Falk Pharma GmbH
- Enrollment
- 345
- Locations
- 1
- Primary Endpoint
- Proportion of recurrence-free patients within 48 weeks
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of the study is to determine whether mesalazine granules compared to placebo is effective in prevention of recurrence of disease.
Detailed Description
The purpose of the study is to demonstrate the superiority of mesalazine granules compared to placebo in terms of the primary efficacy variable proportion of recurrence-free patients within 48 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of left-sided uncomplicated diverticular disease confirmed by ultrasonography or computed tomography
- •Presence of at least one diverticulum of the left colon
- •Most recent attack of left-sided uncomplicated diverticulitis responding to antibiotics and/or dietary modification within the last 6 months
- •C-reactive protein (CRP) \> upper limit of normal (ULN) at the start of the most recent attack
Exclusion Criteria
- •Complicated diverticular disease
- •Right-sided diverticulitis
- •Previous colonic surgery
- •Presence of symptomatic organic disease of the gastrointestinal tract
- •Active colorectal cancer or a history of colorectal cancer
- •Hemorrhagic diathesis
- •Active peptic ulcer disease, local intestinal infection
- •Asthma if careful medical monitoring is not ensured
- •Abnormal hepatic function or liver cirrhosis
- •Abnormal renal function
Arms & Interventions
A
Intervention: Mesalazine
B
Intervention: Placebo
Outcomes
Primary Outcomes
Proportion of recurrence-free patients within 48 weeks
Time Frame: 48 weeks
Secondary Outcomes
- Severity of diarrhea(48 weeks)
- Quality of Life (QoL)(48 weeks)
- Health assessment(48 weeks)
- Occurrence of diverticulitis-associated fever(48 weeks)
- Number of days with left lower quadrant pain(48 weeks)
- Stool consistency(48 weeks)
- Time to recurrence
- Assessment of efficacy by investigator and patient(48 weeks)
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Phase 3
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of DiverticulitisDiverticulitisNCT01038739Dr. Falk Pharma GmbH330
Completed
Phase 2
A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative ColitisUlcerative ColitisNCT00808977Palau Pharma S.L.U.80
Completed
Phase 3
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)Colitis, UlcerativeRecurrenceNCT00746447Dr. Falk Pharma GmbH648
Completed
Phase 3
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.Ulcerative ColitisNCT00737789Ferring Pharmaceuticals206
Completed
Phase 3
Mesalazine Therapy in Patients With Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00626288SOFAR S.p.A.187